{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:25:09Z","timestamp":1791645909204,"version":"4.3.4"},"reference-count":123,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.numecd.2021.11.015","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T18:04:56Z","timestamp":1638295496000},"page":"815-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard I.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.numecd.2021.11.015_bib2","first-page":"e9349","article-title":"Global epidemiology of ischemic heart disease: results from the Global Burden of Disease Study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.numecd.2021.11.015_bib3","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/HJH.0000000000000701","article-title":"Serum uric acid and the risk of cardiovascular and renal disease","volume":"33","author":"Borghi","year":"2015","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.numecd.2021.11.015_bib4","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"issue":"9457","key":"10.1016\/j.numecd.2021.11.015_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0140-6736(05)70240-3","article-title":"Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk","volume":"365","author":"Jackson","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.numecd.2021.11.015_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1253\/circj.CJ-13-1494","article-title":"Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease","volume":"78","author":"Lee","year":"2014","journal-title":"Circ J"},{"issue":"34","key":"10.1016\/j.numecd.2021.11.015_bib7","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2021.11.015_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/2047487317695616","article-title":"UMPIRE investigators. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk","volume":"24","author":"Lafeber","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"33","key":"10.1016\/j.numecd.2021.11.015_bib9","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2021.11.015_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacc.2019.04.047","article-title":"Trajectories of non-HDL cholesterol across midlife: implications for cardiovascular prevention","volume":"74","author":"Pencina","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.numecd.2021.11.015_bib11","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"issue":"32","key":"10.1016\/j.numecd.2021.11.015_bib12","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.numecd.2021.11.015_bib13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2021.11.015_bib14","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2021.11.015_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.numecd.2021.11.015_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijcard.2018.05.098","article-title":"LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial","volume":"271","author":"Verbree-Willemsen","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2021.11.015_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2021.11.015_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/1158822-S0-000000000-00000","article-title":"Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering","volume":"10","author":"Pedersen","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.numecd.2021.11.015_bib19","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib20","doi-asserted-by":"crossref","first-page":"e59233","DOI":"10.1371\/journal.pone.0059233","article-title":"Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity","volume":"8","author":"Xiao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2021.11.015_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/21218","article-title":"Regulation of endothelium-derived nitric oxide production by the protein kinase Akt","volume":"399","author":"Fulton","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.numecd.2021.11.015_bib22","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0735-1097(97)00324-0","article-title":"HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia","volume":"30","author":"Weber","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.numecd.2021.11.015_bib23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.ATV.0000022694.16328.CC","article-title":"Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients","volume":"22","author":"Rezaie-Majd","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.numecd.2021.11.015_bib24","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1476-5381.2009.00612.x","article-title":"Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase\/signal transducers and activators of transcription pathways in human vascular endothelial cells","volume":"159","author":"Jougasaki","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/res.90.3.251","article-title":"Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly","volume":"90","author":"Galis","year":"2002","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.numecd.2021.11.015_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.ATV.0000068646.76823.AE","article-title":"Statins inhibit secretion of metalloproteinases \u22121, \u22122, \u22123, and \u22129 from vascular smooth muscle cells and macrophages","volume":"23","author":"Luan","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"10.1016\/j.numecd.2021.11.015_bib27","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","article-title":"Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study","volume":"64","author":"Komukai","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jacl.2016.01.004","article-title":"Changes in carotid plaque tissue composition in subjects who continued and discontinued statin therapy","volume":"10","author":"Du","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2021.11.015_bib29","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/01.CIR.0000015465.73933.3B","article-title":"Statin prevents tissue factor expression in human endothelial cells: role of Rho\/Rho-kinase and Akt pathways","volume":"105","author":"Eto","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.11.015_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.RES.83.7.683","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins","volume":"83","author":"Essig","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2021.11.015_bib31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/01.ATV.20.2.556","article-title":"HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells","volume":"20","author":"Bourcier","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.11.015_bib32","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/01.ATV.19.7.1812","article-title":"Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin","volume":"19","author":"Alfon","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.11.015_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.numecd.2021.11.015_bib34","doi-asserted-by":"crossref","first-page":"592","DOI":"10.5551\/jat.48603","article-title":"The goal of achieving atherosclerotic plaque regression with lipid-lowering therapy: insights from IVUS trials","volume":"26","author":"Daida","year":"2019","journal-title":"J Atherosclerosis Thromb"},{"issue":"7","key":"10.1016\/j.numecd.2021.11.015_bib35","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1253\/circj.CJ-18-1376","article-title":"Effect of statin therapy on fibrous cap thickness in coronary plaque on optical coherence tomography - review and meta-analysis","volume":"83","author":"Ozaki","year":"2019","journal-title":"Circ J"},{"issue":"13","key":"10.1016\/j.numecd.2021.11.015_bib36","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jacc.2008.09.065","article-title":"Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis","volume":"53","author":"Chhatriwalla","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2021.11.015_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"9753","key":"10.1016\/j.numecd.2021.11.015_bib38","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.11.015_bib39","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2021.11.015_bib40","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib41","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib42","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"9753","key":"10.1016\/j.numecd.2021.11.015_bib43","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"issue":"9841","key":"10.1016\/j.numecd.2021.11.015_bib44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.11.015_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.11.015_bib46","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib49","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.11.015_bib50","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib51","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacc.2005.06.088","article-title":"Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure","volume":"47","author":"Sola","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2021.11.015_bib52","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.numecd.2021.11.015_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11892-017-0837-8","article-title":"Diabetes secondary to treatment with statins","volume":"17","author":"Laakso","year":"2017","journal-title":"Curr Diabetes Rep"},{"issue":"7","key":"10.1016\/j.numecd.2021.11.015_bib54","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2337\/db18-0999","article-title":"Statins promote interleukin-1\u03b2-dependent adipocyte insulin resistance through lower prenylation, not cholesterol","volume":"68","author":"Henriksbo","year":"2019","journal-title":"Diabetes"},{"issue":"Suppl 4","key":"10.1016\/j.numecd.2021.11.015_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/diacare.14.4.39","article-title":"Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors","volume":"14","author":"Berne","year":"1991","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.HYP.0000028979.98877.0C","article-title":"ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO","volume":"40","author":"Shiuchi","year":"2002","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.numecd.2021.11.015_bib57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1161\/01.HYP.0000153321.13792.b9","article-title":"Angiotensin II and the endothelium: diverse signals and effects","volume":"45","author":"Watanabe","year":"2005","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.numecd.2021.11.015_bib58","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/pr.114.010454","article-title":"International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected]","volume":"67","author":"Karnik","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"7","key":"10.1016\/j.numecd.2021.11.015_bib59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: new roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.pcad.2015.11.004","article-title":"The divergent cardiovascular effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on myocardial infarction and death","volume":"58","author":"Strauss","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2021.11.015_bib61","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/hc0402.102619","article-title":"The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part II: AT1 receptor regulation","volume":"105","author":"Nickenig","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.11.015_bib62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.numecd.2021.11.015_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy","volume":"50","author":"Bader","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.numecd.2021.11.015_bib64","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib65","doi-asserted-by":"crossref","first-page":"e90217","DOI":"10.1371\/journal.pone.0090217","article-title":"Angiotensin II receptor blockers improve peripheral endothelial function: a meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.numecd.2021.11.015_bib66","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2021.11.015_bib67","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.numecd.2021.11.015_bib68","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","article-title":"Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox","volume":"135","author":"Strauss","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.numecd.2021.11.015_bib69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","article-title":"ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT","volume":"73","author":"Ceconi","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"9386","key":"10.1016\/j.numecd.2021.11.015_bib70","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib71","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11589400-000000000-00000","article-title":"ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes","volume":"11","author":"Cangiano","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"10.1016\/j.numecd.2021.11.015_bib72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MCA.0b013e32832fa9b8","article-title":"Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression\/regression studies","volume":"20","author":"Bruining","year":"2009","journal-title":"Coron Artery Dis"},{"issue":"6","key":"10.1016\/j.numecd.2021.11.015_bib73","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1161\/01.HYP.0000070956.57418.22","article-title":"Different effect of antihypertensive drugs on conduit artery endothelial function","volume":"41","author":"Ghiadoni","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2021.11.015_bib74","first-page":"514","article-title":"Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease","volume":"60","author":"Krysiak","year":"2008","journal-title":"Pharmacol Rep"},{"issue":"9 Pt 2","key":"10.1016\/j.numecd.2021.11.015_bib75","doi-asserted-by":"crossref","first-page":"142S","DOI":"10.1016\/j.amjhyper.2005.05.037","article-title":"Specific properties and effect of perindopril in controlling the renin-angiotensin system","volume":"18","author":"Ferrari","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.numecd.2021.11.015_bib76","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archinte.1992.00400130082009","article-title":"Serum cholesterol, blood pressure, cigarette smoking and death from coronary artery disease: overall \ufb01ndings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial research group","volume":"152","author":"Neaton","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.numecd.2016.07.013","article-title":"Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia","volume":"27","author":"Borghi","year":"2017","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2021.11.015_bib78","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/00004872-200209000-00016","article-title":"Relative role of systolic, diastolic and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart Study","volume":"20","author":"Borghi","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2021.11.015_bib79","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1053\/euhj.2001.2888","article-title":"Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women","volume":"23","author":"Thomas","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2021.11.015_bib80","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1161\/01.HYP.0000165672.69176.ed","article-title":"Relationship of office, home and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population","volume":"45","author":"Mancia","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2021.11.015_bib81","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/clp.11.23","article-title":"From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study","volume":"6","author":"Cicero","year":"2011","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.numecd.2021.11.015_bib82","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000013862.13962.1D","article-title":"The impact of JNC-VI guidelines on treatment recommendations in the US population","volume":"39","author":"Muntner","year":"2002","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.numecd.2021.11.015_bib83","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1096\/fj.15-271627","article-title":"Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptor","volume":"29","author":"Yamamoto","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.numecd.2021.11.015_bib84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/07853890008995944","article-title":"Angiotensin AT1 receptor over-expression in hypercholesterolaemia","volume":"32","author":"Strehlow","year":"2000","journal-title":"Ann Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-9150(99)00145-8","article-title":"Angiotensin II atherogenicity in apolipoprotein E de\ufb01cient mice is associated with increased cellular cholesterol biosynthesis","volume":"146","author":"Keidar","year":"1999","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.numecd.2021.11.015_bib86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.HYP.0000024348.87637.6F","article-title":"Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress","volume":"40","author":"Delbosc","year":"2002","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.numecd.2021.11.015_bib87","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1042\/CS20030127","article-title":"Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits","volume":"105","author":"Oubi\u00f1a","year":"2003","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.numecd.2021.11.015_bib88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2005.01.045","article-title":"Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis","volume":"182","author":"Grothusen","year":"2005","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.numecd.2021.11.015_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00005344-199807000-00005","article-title":"Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril","volume":"32","author":"Kowala","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6 Pt 2","key":"10.1016\/j.numecd.2021.11.015_bib90","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.1016\/S0895-7061(01)02070-2","article-title":"Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition","volume":"14","author":"Dechend","year":"2001","journal-title":"Am J Hypertens"},{"issue":"6","key":"10.1016\/j.numecd.2021.11.015_bib91","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/07853890310001294","article-title":"A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms","volume":"35","author":"Nakagami","year":"2003","journal-title":"Ann Med"},{"key":"10.1016\/j.numecd.2021.11.015_bib92","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/01.CIR.100.21.2131","article-title":"Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men","volume":"100","author":"Nickenig","year":"1999","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.numecd.2021.11.015_bib93","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/HJH.0000000000001325","article-title":"Adjunctive therapy with statins reduces residual albuminuria\/proteinuria and provides further renoprotection by downregulating the angiotensin II-AT1 pathway in hypertensive nephropathy","volume":"35","author":"Zhang","year":"2017","journal-title":"J Hypertens"},{"issue":"24","key":"10.1016\/j.numecd.2021.11.015_bib94","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1161\/01.CIR.0000143085.86697.13","article-title":"Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients","volume":"110","author":"Koh","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.numecd.2021.11.015_bib95","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2006.01.021","article-title":"The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients","volume":"190","author":"Han","year":"2007","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.numecd.2021.11.015_bib96","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1161\/01.HYP.0000166722.91714.ba","article-title":"Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes","volume":"45","author":"Koh","year":"2005","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.numecd.2021.11.015_bib97","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1161\/01.CIR.0000165070.46111.9F","article-title":"Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients","volume":"111","author":"Ceriello","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2021.11.015_bib98","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1472-8206.2011.00975.x","article-title":"Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein","volume":"26","author":"Abdel-Zaher","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.numecd.2021.11.015_bib99","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.diabres.2013.12.060","article-title":"Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: an observational study","volume":"103","author":"Faglia","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.numecd.2021.11.015_bib100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/jch.12081","article-title":"Antihypertensive effects of statins: a meta-analysis of prospective controlled studies","volume":"15","author":"Briasoulis","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"10.1016\/j.numecd.2021.11.015_bib101","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/01.HYP.0000259737.43916.42","article-title":"Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials","volume":"49","author":"Strazzullo","year":"2007","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.numecd.2021.11.015_bib102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11906-001-0090-y","article-title":"Statins and blood pressure regulation","volume":"3","author":"Borghi","year":"2001","journal-title":"Curr Hypertens Rep"},{"issue":"24","key":"10.1016\/j.numecd.2021.11.015_bib103","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehl403","article-title":"Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian cardiac outcomes trial","volume":"27","author":"Sever","year":"2006","journal-title":"Eur Heart J"},{"issue":"9489","key":"10.1016\/j.numecd.2021.11.015_bib104","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"issue":"10153","key":"10.1016\/j.numecd.2021.11.015_bib105","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(18)31776-8","article-title":"Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial","volume":"392","author":"Gupta","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib106","article-title":"Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study","volume":"20","author":"Ruszkowski","year":"2019","journal-title":"J Renin-Angiotensin-Aldosterone Syst JRAAS"},{"issue":"11","key":"10.1016\/j.numecd.2021.11.015_bib107","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.jhh.1001748","article-title":"Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease","volume":"18","author":"Athyros","year":"2004","journal-title":"J Hum Hypertens"},{"issue":"12","key":"10.1016\/j.numecd.2021.11.015_bib108","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.amjcard.2007.07.025","volume":"100","author":"Fujita","year":"2007","journal-title":"Am J Cardiol"},{"issue":"suppl 2","key":"10.1016\/j.numecd.2021.11.015_bib109","first-page":"A18906","article-title":"Combining perindopril with a calcium channel blocker and a lipid lowering agent significantly decreases mortality: a subgroup analysis of EUROPA","volume":"128","author":"Bertrand","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.numecd.2021.11.015_bib110","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1161\/ATVBAHA.107.149039","article-title":"Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin\/ACE-inhibitor combination","volume":"27","author":"Radaelli","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2021.11.015_bib111","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2019.08.018","article-title":"A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents","volume":"289","author":"Kim","year":"2019","journal-title":"Atherosclerosis"},{"issue":"e-supplement A","key":"10.1016\/j.numecd.2021.11.015_bib112","article-title":"Combined ACE inhibitor and statin therapy in hypertensive diabetic patients prior to acute myocardial infarction have protective effects on hospital morbidity and mortality","volume":"28","author":"Ilic","year":"2010","journal-title":"J Hypertens"},{"issue":"8","key":"10.1016\/j.numecd.2021.11.015_bib113","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1212\/01.wnl.0000208406.45440.84","article-title":"Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk","volume":"66","author":"Kumar","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.numecd.2021.11.015_bib114","first-page":"e88","article-title":"Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications","volume":"15","author":"Dudl","year":"2009","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.numecd.2021.11.015_bib115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40268-018-0255-7","article-title":"Post hoc analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II observational studies in mild to moderate hypertensive patients treated with perindopril and atorvastatin concomitantly","volume":"18","author":"Sampalis","year":"2018","journal-title":"Drugs R D"},{"issue":"13","key":"10.1016\/j.numecd.2021.11.015_bib116","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/hc3801.095585","article-title":"Are ACE inhibitors a \"magic bullet\" against oxidative stress?","volume":"104","author":"M\u00fcnzel","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.numecd.2021.11.015_bib117","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.96.5.1631","article-title":"Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation","volume":"96","author":"Wong","year":"1997","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.numecd.2021.11.015_bib118","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/heart.88.5.525","article-title":"Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP","volume":"88","author":"Reinhardt","year":"2002","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.numecd.2021.11.015_bib119","doi-asserted-by":"crossref","first-page":"e0178278","DOI":"10.1371\/journal.pone.0178278","article-title":"Fluvastatin inhibits AGE-induced cell proliferation and migration via an ERK5-dependent Nrf2 pathway in vascular smooth muscle cells","volume":"12","author":"Hwang","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.numecd.2021.11.015_bib120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardiores.2005.07.002","article-title":"Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho\/Rho-kinase pathway","volume":"68","author":"Kozai","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.numecd.2021.11.015_bib121","first-page":"1291","article-title":"Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury","volume":"139","author":"Prescott","year":"1991","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.numecd.2021.11.015_bib122","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.tcm.2006.03.003","article-title":"The nonlipid effects of statins on endothelial function","volume":"16","author":"Beckman","year":"2006","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.numecd.2021.11.015_bib123","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2011.02.044","article-title":"Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials","volume":"216","author":"Shahin","year":"2011","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.numecd.2021.11.015_bib124","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/MOL.0000000000000769","article-title":"New insights in statins affecting atheromatous plaque macrophages","volume":"32","author":"H\u00e4rdtner","year":"2021","journal-title":"Curr Opin Lipidol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321005561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321005561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:21:14Z","timestamp":1760545274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321005561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0939475321005561"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.11.015","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}]}}